Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | SELE | P16581 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.32 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.32 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.32 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.32 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.32 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15575294 | 0.83 | CLK1 (0.43) | HCAR2CLK1DYRK1ADYRK1BICAM1 | |
| SCHEMBL9608839 | 0.82 | HCAR2 (0.62) | HCAR2ICAM1SELEHSD17B1HSD17B2 | |
| SCHEMBL10183970 | 0.81 | CLK1 (0.42) | HCAR2CLK1DYRK1ADYRK1BICAM1 | |
| SCHEMBL19764489 | 0.78 | CLK1 (0.40) | HCAR2CLK1DYRK1ADYRK1BICAM1 | |
| SCHEMBL20487461 | 0.78 | CLK1 (0.40) | HCAR2CLK1DYRK1ADYRK1BICAM1 | |
| SCHEMBL23039876 | 0.76 | CLK1 (0.39) | HCAR2CLK1DYRK1ADYRK1BICAM1 | |
| SCHEMBL17747762 | 0.75 | FAAH (0.40) | CLK1DYRK1ADYRK1BICAM1SELE | |
| SCHEMBL2073998 | 0.75 | NPC1 (0.58) | TRPM8HSD17B1HSD17B2HDAC6STS | |
| SCHEMBL1107386 | 0.74 | HCAR2 (0.68) | HCAR2ICAM1SELEALDH1A1KDM4E | |
| SCHEMBL12677932 | 0.74 | HCAR2 (0.56) | HCAR2ALDH1A1KDM4EHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4467199-A2 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2024-11-27 | — | — | EP | disclosed |
| CN-118908957-A | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-3976597-B1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-28 | — | — | EP | disclosed |
| CN-114222737-B | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-20 | — | — | US | disclosed |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| US-20230080834-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3976597-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | Janssen Pharmaceutica NV (BE) | 2022-04-06 | — | — | EP | disclosed |
| CN-114222737-A | Small molecule inhibitor of NF-kB induced kinase | 詹森药业有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11254673-B2 | Small molecule inhibitors of NF-κB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| US-20210300918-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020239999-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300918-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, NFRKB | HCAR2 1331/4885CLK1 208/4885DYRK1A 942/4885 |
| US-20230080834-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, NFRKB | HCAR2 1331/4885CLK1 208/4885DYRK1A 942/4885 |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | NFKBIA, IKBKB, NFRKB | HCAR2 1331/4885CLK1 208/4885DYRK1A 942/4885 |
| US-11254673-B2 | Small molecule inhibitors of NF-κB inducing kinase | NFKBIA, IKBKB, CHUK | HCAR2 1192/4885CLK1 292/4885DYRK1A 1078/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | HCAR2 960/4885CLK1 391/4885DYRK1A 2362/4885 |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, IKBKE | HCAR2 1393/4885CLK1 214/4885DYRK1A 949/4885 |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | HCAR2 2404/4885CLK1 4700/4885DYRK1A 4002/4885 |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | HCCS, HAVCR2, SLC10A1 | HCAR2 2404/4885CLK1 4700/4885DYRK1A 4002/4885 |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | HCAR2 2404/4885CLK1 4700/4885DYRK1A 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.